
CBSE's Sugar Board essential public health measure, aligns with global nutrition goals: Experts
The recent directive by the Central Board of Secondary Education (CBSE) to install "Sugar Boards" in schools is an essential public health measure that also aligns with global nutrition goals, said health experts on Tuesday.
Amid increasing cases of diabetes and obesity among young children, the CBSE, last week, instructed over 24,000 affiliated schools across India to establish sugar boards.
The Sugar Boards will provide essential information, including recommended sugar intake, the sugar content in commonly consumed foods (such as junk food and cold drinks), health risks associated with high sugar consumption, and healthier dietary alternatives.
'This initiative educates children about the dangers of excessive sugar consumption, which is a major contributor to childhood obesity and Type 2 diabetes. By clearly displaying recommended sugar intake and the sugar content in common foods, the boards promote awareness and healthier choices,' Dr Naval Vikram, Professor of Medicine, at AIIMS, New Delhi, told IANS
'Coupled with workshops and parental involvement, this approach can reshape dietary habits early in life. It's a timely and necessary public health measure that aligns with global nutrition goals and helps build a foundation for long-term wellness among Indian children,' added the expert.
Type 2 diabetes, once only prevalent in adults and the elderly, is now more common among children.
In the letter to school principals, the CBSE attributed the alarming trend, seen particularly in the last decade, to high sugar intake, often due to the easy availability of sugary snacks, beverages, and processed foods within school environments.
The World Health Organization (WHO) recommends a reduced intake of added sugar throughout one's life. In both adults and children, WHO recommends reducing the intake of free sugars to less than 10 per cent of total energy intake. The UN health body suggests a further reduction of the intake of free sugars to below 5 per cent of total energy intake.
'Studies have indicated that sugar constitutes 13 per cent of daily calorie intake for children aged 4 to 10 years, and 15 per cent for those aged 11 to 18 years, substantially exceeding the recommended limit of 5 per cent,' the letter said.
The CBSE noted that the 'proliferation of sugary snacks, beverages, and processed foods, often readily available in school environments, contributes significantly to this excessive intake'.
The new Sugar Board will educate students about informed food choices and promote long-term health benefits among students, it said.
'I would say it is a good step but to reduce consumption of unhealthy food products lot more needs to be done, including regulation for warning labels and ban of advertising of products High in Fat, Salt, and Sugar (HFSS). Even if you focus only on schools, the canteen should be made 'HFSS-free',' said Dr. Arun Gupta, a New-based paediatrician, told IANS.
In addition to the risk of diabetes, the excessive consumption of sugar also contributes to obesity, dental problems, and other metabolic disorders, ultimately impacting children's long-term health and academic performance.
Dr. Harsh Mahajan Chair-FICCI Health Services Committee, called the initiative "a timely and much-needed".
He noted that while lifestyle-related disorders are beginning to affect children at a much earlier age, worryingly many of these conditions remain undiagnosed until much later, when irreversible damage has already occurred'. The experts also urged parents and schools to consider regular screening tests like fasting blood sugar, HbA1c, liver function, lipid profile, BMI, and waist circumference to help understand children's health and to make early changes.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Economic Times
10 minutes ago
- Economic Times
KKR-backed IVI to buy ART Fertility Clinics for $450 million
Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel KKR-backed IVI RMA Global, a US-based leader in infertility treatment, is set to acquire ART Fertility Clinics for $400-450 million, according to people familiar with the matter. The acquisition marks a significant step in IVI RMA's global expansion, adding India to its presence in over 15 countries and more than 190 clinical offices across the US, Europe and Latin parties are in the final stages of documentation for a shareholders' agreement and are hoping to wrap up the transaction by June with private hospitals, the IVF industry in India too is witnessing consolidation as several private equity funds have been aggressive with acquisitions. In 2023, Swedish fund EQT Partners acquired a significant majority stake in Indira IVF, the largest provider of fertility services in India and top five globally in terms of annual IVF cycles, at a $1.1 billion ('9,000 crore) Fertility Clinics began in 2015 as IVI Middle East, an international arm of IVI RMA Global. In 2020, IVI RMA divested the business to Gulf Capital, which rebranded it as ART Fertility Clinics. Since then, the brand has rapidly grown, expanding across West Asia and clinics in Abu Dhabi, Dubai and Al Ain in the UAE as well as 11 centres across India, ART Fertility has established itself as a high-performance network in reproductive medicine. The Indian expansion began in 2021, backed by a $30 million investment from Gulf Fertility operates in big Indian cities including Mumbai, Noida, Ahmedabad, Chennai, Hyderabad, Gurgaon and by Suresh Soni, former co-founder and CEO of Nova IVF Fertility, ART Fertility reports a pregnancy success rate of 70% and has recorded over 5,000 successful pregnancies in under nine to sources, ART Fertility posted revenue of $100-120 million in FY25, with an estimated Ebitda of $35 million."For an Indian healthcare player, a $25-35 million ebitda which is borderline ebitda positive coming from the Middle East would add no value," said a fund manager at a Mumbai-based private equity firm that operates a pan-India IVF chain. "However, IVI being a US player where multiples are low, adding a Middle East business works well."IVI RMA trumped a rival bid by Temasek-backed Cloudnine Hospitals.A KKR spokesperson declined to comment. IVI RMA and ART Fertility did not respond to is the advisor in the is rapidly emerging as one of the world's fastest-growing markets for Assisted Reproductive Technology (ART). However, the sector has scope for expansion at 210 IVF cycles per million people, compared with 1,200 in the US and over 2,000 in affects approximately 15% of Indian couples, a figure expected to rise due to lifestyle factors such as poor diet, stress, late marriages, and to EY, India's IVF market is expected to grow from $793 million in 2020 to $1.45 billion by 2027, at a projected CAGR of 15-20%.India sees around 300,000 IVF cycles annually, with projections suggesting this could grow to 500,000-600,000 cycles by 2030. About 30% of the market is controlled by 10-15 organised players, while the remaining is fragmented among smaller, unorganised clinics. Key players in India's fertility sector include Indira IVF, Nova IVF, Oasis IVF, Bloom Fertility Centre, Bengaluru-based Milann, Morpheus IVF, Ridge IVF, Akanksha IVF and Bourn Hall IVF, the second largest player in India, is owned by Asia Healthcare Holdings (AHH), the single specialty hospitals platform backed by GIC and homegrown PE fund Kedaara Capital owns a minority stake in Oasis Fertility, while Brussels-based fund Verlinvest owns a controlling stake in Ferty9 F, a premier chain of fertility clinics in the AP/Telangana region.


Time of India
35 minutes ago
- Time of India
Seminar on MBBS, global education pathways in Pune draws enthusiastic response
1 2 P une: A large gathering of aspiring students and parents attended an informative Mission Admission seminar organised by The Times of India jointly with The Astute Academy at Dr. Kalmadi Shamarao Junior College auditorium on Sunday. Conducted by Tushar Vinod Deoras, a former BARC scientist and chairman of Astute Academy, the seminar aimed to demystify the complexities of Indian and international admissions for MBBS and higher education. The first session focused on the Indian MBBS admission process, offering clarity for students with NEET scores as low as 200. Attendees also learned about affordable pathways to study medicine in the United States through structured Indo-American university collaborations. The second session delved into undergraduate and postgraduate admissions in the US and Germany. Parents and students were provided with detailed guidance on securing spots at prestigious universities abroad. During the first session, Deoras shared a wealth of information. He pointed out that many private medical colleges offer donation-free management quota merit seats. He explained fee structures, wherein funding is controlled by govt, and proposed to students tripartite Indo-American university partnered systems, which provide affordable, sophisticated modern medical education in the US and subsequently offer employer-relevant value around the globe. The second session was about undergraduate and postgraduate courses offered in the US and Germany, particularly emphasising on Ivy League schools and Germany's technical universities. Deoras noted how flexible and multidisciplinary the US system is, with more emphasis on career focus than rigid course structures. He urged students to start building their profiles as early as Std IX and to apply to international universities at least one year in advance, as most operate on a first-come, first-served basis. He said, "Quality education and a successful career are a student's fundamental right. Students and parents should not judge countries by stereotypes but understand which system aligns best with the student's goals." A highlight of the seminar was its interactive nature. One parent shared, "The session was very enlightening. Many doubts regarding my son's education were resolved, and I feel much more at peace now." Another participant raised a query about dentistry as a career path, to which Deoras responded that it remains an underappreciated but highly rewarding field in India. While initial years in practice may be challenging, dentistry offers significant long-term growth and financial prospects. Deoras also addressed several audience questions about state-wise admission quotas for MBBS, the application process for foreign universities, and the admission timelines and requirements for medical education abroad. The seminar concluded with a positive response from the audience who appreciated the transparency, practical guidance, and motivational approach.


Time of India
an hour ago
- Time of India
KKR-backed IVI to buy ART Fertility Clinics for $450 million
KKR-backed IVI RMA Global, a US-based leader in infertility treatment, is set to acquire ART Fertility Clinics for $400-450 million, according to people familiar with the matter. The acquisition marks a significant step in IVI RMA's global expansion, adding India to its presence in over 15 countries and more than 190 clinical offices across the US, Europe and Latin America. Both parties are in the final stages of documentation for a shareholders' agreement and are hoping to wrap up the transaction by June end. As with private hospitals, the IVF industry in India too is witnessing consolidation as several private equity funds have been aggressive with acquisitions. In 2023, Swedish fund EQT Partners acquired a significant majority stake in Indira IVF, the largest provider of fertility services in India and top five globally in terms of annual IVF cycles, at a $1.1 billion ('9,000 crore) valuation. ART Fertility Clinics began in 2015 as IVI Middle East, an international arm of IVI RMA Global. In 2020, IVI RMA divested the business to Gulf Capital, which rebranded it as ART Fertility Clinics. Since then, the brand has rapidly grown, expanding across West Asia and India. Live Events With clinics in Abu Dhabi, Dubai and Al Ain in the UAE as well as 11 centres across India, ART Fertility has established itself as a high-performance network in reproductive medicine. The Indian expansion began in 2021, backed by a $30 million investment from Gulf Capital. ART Fertility operates in big Indian cities including Mumbai, Noida, Ahmedabad, Chennai, Hyderabad, Gurgaon and Faridabad. Led by Suresh Soni, former co-founder and CEO of Nova IVF Fertility, ART Fertility reports a pregnancy success rate of 70% and has recorded over 5,000 successful pregnancies in under nine years. According to sources, ART Fertility posted revenue of $100-120 million in FY25, with an estimated Ebitda of $35 million. "For an Indian healthcare player, a $25-35 million ebitda which is borderline ebitda positive coming from the Middle East would add no value," said a fund manager at a Mumbai-based private equity firm that operates a pan-India IVF chain. "However, IVI being a US player where multiples are low, adding a Middle East business works well." IVI RMA trumped a rival bid by Temasek-backed Cloudnine Hospitals. A KKR spokesperson declined to comment. IVI RMA and ART Fertility did not respond to queries. Moelis is the advisor in the transaction. India is rapidly emerging as one of the world's fastest-growing markets for Assisted Reproductive Technology (ART). However, the sector has scope for expansion at 210 IVF cycles per million people, compared with 1,200 in the US and over 2,000 in Europe. Infertility affects approximately 15% of Indian couples, a figure expected to rise due to lifestyle factors such as poor diet, stress, late marriages, and pollution. According to EY, India's IVF market is expected to grow from $793 million in 2020 to $1.45 billion by 2027, at a projected CAGR of 15-20%. India sees around 300,000 IVF cycles annually, with projections suggesting this could grow to 500,000-600,000 cycles by 2030. About 30% of the market is controlled by 10-15 organised players, while the remaining is fragmented among smaller, unorganised clinics. Key players in India's fertility sector include Indira IVF, Nova IVF, Oasis IVF, Bloom Fertility Centre, Bengaluru-based Milann, Morpheus IVF, Ridge IVF, Akanksha IVF and Bourn Hall Clinic. Nova IVF, the second largest player in India, is owned by Asia Healthcare Holdings (AHH), the single specialty hospitals platform backed by GIC and TPG. Similarly, homegrown PE fund Kedaara Capital owns a minority stake in Oasis Fertility, while Brussels-based fund Verlinvest owns a controlling stake in Ferty9 F, a premier chain of fertility clinics in the AP/Telangana region.